Recently, findings of the phase I part of a phase I–II trial of Novavax’s vaccine candidate, which began in May 2020, were released in the New England Journal of Medicine. The vaccine candidate, called NVX-CoV2373, is a recombinant SARS-CoV-2 nanoparticle vaccine created from the full-length, wild-type, virus spike (S) glycoprotein which mediates viral entry in the host cell. The first of its type to undergo human trials for SARS-CoV-2. The primary aim of this randomized, placebo-controlled, trial (which enrolled healthy adult volunteers under the age of 60 from two locations in Australia) …